Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Neil R Michaud"'
Autor:
Vahe Bedian, David C. Blakey, Diane M. Simeone, Robert E. Hollingsworth, Christopher Frantz, Meina Liang, Elaine Hurt, David W. Jenkins, Naomi Laing, Jelena Jovanović, Jaspal S. Kang, Lidong Wang, Matthew A. Belmonte, Mark J. Hynes, Jon W. Chesebrough, Sanjoo Jalla, Axel Hernandez, Anne Marie Mazzola, Jerold J. Jordan, Kristen A. McEachern, Youzhen Wang, Neil R. Michaud
Supplementary Materials and Methods; Supplementary Figure S1. Binding kinetics of hedgehog antibodies to human and mouse hedgehog proteins using surface plasmon resonance. Supplementary Figure S2. Hedgehog ligands stimulate mGLI1 reporter activity an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08f01c40dab06dfb8ce31bb83ff4b4fb
https://doi.org/10.1158/1535-7163.22501233
https://doi.org/10.1158/1535-7163.22501233
Autor:
Marjorie G, Zauderer, Peter W, Szlosarek, Sylvestre, Le Moulec, Sanjay, Popat, Paul, Taylor, David, Planchard, Arnaud, Scherpereel, Marianna, Koczywas, Martin, Forster, Robert B, Cameron, Tobias, Peikert, Evren Kocabaş, Argon, Neil R, Michaud, Attila, Szanto, Jay, Yang, Yingxue, Chen, Vikram, Kansra, Shefali, Agarwal, Dean A, Fennell
Publikováno v:
The Lancet Oncology. 23:758-767
Treatment options for malignant pleural mesothelioma are scarce. Tazemetostat, a selective oral enhancer of zeste homolog 2 (EZH2) inhibitor, has shown antitumour activity in several haematological cancers and solid tumours. We aimed to evaluate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a72bb5e619e517ad1775251f5dfb62f3
https://doi.org/10.1016/s1470-2045(22)00277-7
https://doi.org/10.1016/s1470-2045(22)00277-7
Autor:
Travis J. Hollmann, Meera Hameed, Neil R. Michaud, Steven J. Blakemore, Scott R. Daigle, Eric Lis, Lev Roshal, Guo Zhu, Mrinal M. Gounder
Supplementary Materials and Methods Supplementary Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9093720357000ff5d2ac7f95084982d6
https://doi.org/10.1158/1078-0432.22474526
https://doi.org/10.1158/1078-0432.22474526
Autor:
Travis J. Hollmann, Meera Hameed, Neil R. Michaud, Steven J. Blakemore, Scott R. Daigle, Eric Lis, Lev Roshal, Guo Zhu, Mrinal M. Gounder
Purpose:We sought to determine the mechanism of an exceptional response in a patient diagnosed with a SMARCB1/INI1-negative chordoma treated with tazemetostat, an EZH2 inhibitor, and followed by radiotherapy.Patient and Methods: In an attempt to inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021aac7d8ce9e1db3548eef4761a7c62
https://doi.org/10.1158/1078-0432.c.6528812
https://doi.org/10.1158/1078-0432.c.6528812
Autor:
Christopher K Rushton, Ryan N Rys, Elizabeth Chavez, Laura K Hilton, Miguel Alcaide, Kostiantyn Dreval, Matthew Cheung, Manuela Cruz, Krysta M. Coyle, Barbara Meissner, Susana Ben-Neriah, Neil R. Michaud, Scott Daigle, Jordan Davidson, Jasper Wong, Annette E. Hay, Michael D. Jain, Lois E. Shepherd, Marco A. Marra, John Kuruvilla, Michael Crump, Koren Kathleen Mann, Sarit Assouline, Christian Steidl, David W. Scott, Nathalie A. Johnson, Ryan D. Morin
Publikováno v:
Blood. 140:9259-9260
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::560c1870e98cfcd4a48de04396d0c117
https://doi.org/10.1182/blood-2022-169623
https://doi.org/10.1182/blood-2022-169623
Autor:
Aixiang Jiang, Stephen Yu, Matthew C. Cheung, Ryan D. Morin, Scott R. Daigle, Koren K. Mann, Neil R Michaud, Christopher Rushton, Nicole Thomas, Michael D. Jain, Joseph M. Connors, Lois E. Shepherd, Krysta M. Coyle, Miguel Alcaide, Kevin Bushell, John Kuruvilla, Nathalie A. Johnson, Marco A. Marra, Christian Steidl, Kirstie L. S. Cleary, David Scott, Mark S. Cragg, Sarah E. Arthur, Sarit Assouline, Jordan Davidson, Michael Crump, Ryan N Rys, Laura K. Hilton
Publikováno v:
Blood Adv
Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with immunochemotherapy containing rituximab (rituximab, cyclophosphamide, hydroxydaunorubicin-vincristine (Oncovin), and prednisone [R-CHOP]); however, prognosis is extremely poor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83780e8865013c6b0ea8ed179bbf1ceb
https://doi.org/10.1182/bloodadvances.2020001696
https://doi.org/10.1182/bloodadvances.2020001696
Autor:
Gilles Salles, Lanie Happ, Neil R Michaud, Christopher Yasso, Sandeep S. Dave, Connie Lee Batlevi, Tycel Phillips, Franck Morschhauser, Jay Yang, Deyaa Adib
Publikováno v:
Blood. 138:1183-1183
Background: Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator implicated as a genetic driver in multiple lymphoma types. Approximately 20% of patients with follicular lymphoma (FL) present with activating, gain-of-function (GoF) EZH2 muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d7d391db7ae3e6e9db6b15b2ca7b341
https://doi.org/10.1182/blood-2021-151452
https://doi.org/10.1182/blood-2021-151452
Autor:
Lois E. Shepherd, Stephen Yu, Ryan N Rys, Ryan D. Morin, Kevin Bushell, Sarit Assouline, Jordan Davidson, Koren K. Mann, John Kuruvilla, Sarah E. Arthur, Nathalie A. Johnson, David Scott, Michael Crump, Christian Steidl, Christopher Rushton, Miguel Alcaide, Joseph M. Connors, Marco A. Marra, Marquisa Zrymiak, Michael D. Jain, Matthew C. Cheung, Scott R. Daigle, Neil R Michaud
Publikováno v:
Blood. 136:8-9
Introduction Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) are treated with standard frontline immunochemotherapy (R-CHOP). However, for cases where R-CHOP fails (relapsed-refractory DLBCL, rrDLBCL), prognosis is extremely poor, with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff1bccd1813ccde0a0c2b86fc199ad23
https://doi.org/10.1182/blood-2020-142871
https://doi.org/10.1182/blood-2020-142871
Autor:
Michael Crump, Sarit Assouline, Nicole Thomas, Neil R Michaud, Marco A. Marra, Christopher Rushton, Laura K. Hilton, Kevin Bushell, Ryan N Rys, Kirstie L. S. Cleary, Ryan D. Morin, Sarah E. Arthur, Koren K. Mann, Aixiang Jiang, Michael D. Jain, John Kuruvilla, Mark S. Cragg, Nathalie A. Johnson, Krysta M. Coyle, Matthew C. Cheung, Christian Steidl, Lois E. Shepherd, Miguel Alcaide, David Scott
Publikováno v:
Blood Cancer Discovery. 1:IA42-IA42
A significant proportion of diffuse large B-cell lymphoma (DLBCL) patients treated with immunochemotherapy containing rituximab (R-CHOP) exhibit either primary or acquired treatment resistance. The advancement of therapeutics in the relapse setting h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a3ad2b2e27aa06c9594173f50c0ae3f
https://doi.org/10.1158/2643-3249.lymphoma20-ia42
https://doi.org/10.1158/2643-3249.lymphoma20-ia42
Autor:
Neil R Michaud, Scott R. Daigle, Meera Hameed, Eric Lis, Guo Zhu, Lev Roshal, Mrinal M. Gounder, Travis J. Hollmann, Stephen J. Blakemore
Publikováno v:
Clin Cancer Res
Purpose: We sought to determine the mechanism of an exceptional response in a patient diagnosed with a SMARCB1/INI1-negative chordoma treated with tazemetostat, an EZH2 inhibitor, and followed by radiotherapy. Patient and Methods: In an attempt to in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::847e2ad53897e8e4a9dca828c738951b
https://pubmed.ncbi.nlm.nih.gov/30642912
https://pubmed.ncbi.nlm.nih.gov/30642912